1. Home
  2. ECOR vs XLO Comparison

ECOR vs XLO Comparison

Compare ECOR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECOR
  • XLO
  • Stock Information
  • Founded
  • ECOR 2005
  • XLO 2016
  • Country
  • ECOR United States
  • XLO United States
  • Employees
  • ECOR N/A
  • XLO N/A
  • Industry
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECOR Health Care
  • XLO Health Care
  • Exchange
  • ECOR Nasdaq
  • XLO Nasdaq
  • Market Cap
  • ECOR 39.7M
  • XLO 35.7M
  • IPO Year
  • ECOR 2018
  • XLO 2021
  • Fundamental
  • Price
  • ECOR $7.75
  • XLO $0.70
  • Analyst Decision
  • ECOR Strong Buy
  • XLO Buy
  • Analyst Count
  • ECOR 2
  • XLO 1
  • Target Price
  • ECOR $25.50
  • XLO $4.00
  • AVG Volume (30 Days)
  • ECOR 118.8K
  • XLO 315.7K
  • Earning Date
  • ECOR 08-06-2025
  • XLO 08-07-2025
  • Dividend Yield
  • ECOR N/A
  • XLO N/A
  • EPS Growth
  • ECOR N/A
  • XLO N/A
  • EPS
  • ECOR N/A
  • XLO N/A
  • Revenue
  • ECOR $26,458,000.00
  • XLO $9,274,000.00
  • Revenue This Year
  • ECOR $23.21
  • XLO $300.08
  • Revenue Next Year
  • ECOR $44.10
  • XLO $1.87
  • P/E Ratio
  • ECOR N/A
  • XLO N/A
  • Revenue Growth
  • ECOR 41.54
  • XLO N/A
  • 52 Week Low
  • ECOR $4.47
  • XLO $0.62
  • 52 Week High
  • ECOR $19.49
  • XLO $1.70
  • Technical
  • Relative Strength Index (RSI)
  • ECOR 64.43
  • XLO 45.89
  • Support Level
  • ECOR $6.57
  • XLO $0.66
  • Resistance Level
  • ECOR $7.80
  • XLO $0.75
  • Average True Range (ATR)
  • ECOR 0.74
  • XLO 0.03
  • MACD
  • ECOR 0.03
  • XLO -0.00
  • Stochastic Oscillator
  • ECOR 63.97
  • XLO 37.72

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Share on Social Networks: